Regeneron Pharma (REGN) PT Cut at Baird on 'Uneventful Earnings'

November 4, 2016 12:40 PM EDT
Get Alerts REGN Hot Sheet
Price: $372.71 -0.76%

Rating Summary:
    19 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade REGN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst Brian Skorney lowered his price target on Neutral-rated Regeneron Pharma (NASDAQ: REGN) to $379.00 (from $448.00) following "uneventful earnings."

Skorney commented, "Though earnings were relatively uneventful and the company pulled out an EPS beat on lower operating expenses, Eylea growth continues to slow ahead of a high-cost 2017 as dupilumab and (mostly likely) sarilumab are launched. We continue to expect the Street to take down estimates on the Sanofi collaboration as Praluent sales stagnate, reimbursement of R&D expenses flatten, and sarilumab launch is delayed. We are lowering our price target to $379."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $336.01 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird, Earnings

Add Your Comment